

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Kashmiri *et al.*


Art Unit: 1642

Application No. 09/830,748

CERTIFICATE OF MAILING

Filed: April 30, 2001

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on May 12, 2003 as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, PO BOX 1450, ALEXANDRIA, VA 22313-1450.



For: VARIANTS OF HUMANIZED ANTI-CARCINOMA MAB CC49

Susan Alpert Siegel, Ph.D.
Agent for Applicant

Examiner: Larry Ronald Helms

Date: May 12, 2003

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(3)

COMMISSIONER FOR PATENTS
 PO BOX 1450
 ALEXANDRIA, VA 22313-1450


Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent. The filing of this Supplemental Information Disclosure Statement should not be construed to be an admission that the information cited in this Statement is, or is considered to be, prior art with respect to the present application.

Applicants filed this Information Disclosure Statement before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this Information Disclosure Statement, please charge any such fees to Deposit Account No. 02-4550. A duplicate copy of this Information Disclosure Statement is enclosed.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By


 Susan Alpert Siegel, Ph.D.
 Registration No. 43,121

One World Trade Center, Suite 1600
 121 S.W. Salmon Street
 Portland, Oregon 97204
 Telephone: (503) 226-7391
 Facsimile: (503) 228-9446

EXHIBIT

tabber

A

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT
BY APPLICANT**

Attorney Docket Number	4239-61725
Application Number	09/830,748
Filing Date	April 30, 2001
First Named Inventor	Kashmiri
Art Unit	1642
Examiner Name	Larry Ronald Helms

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Name
		5,994,511	11/30/99	Lowman <i>et al.</i>
		6,054,297	4/25/00	Carter <i>et al.</i>
		6,180,370	1/30/01	Queen <i>et al.</i>

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Country
		WO 96/13594	5/9/96	
		WO 97/26010	7/24/97	
		WO 99/43816	9/2/99	

OTHER DOCUMENTS

	Hakimi <i>et al.</i> , "Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys," <i>J. Immunol.</i> 147:1352-1359, 1991.
	Iwahashi <i>et al.</i> , "CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity," <i>Mol. Immunol.</i> 36:1079-1091:1999.
	Kashmiri <i>et al.</i> , "Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49," <i>Crit. Rev. Oncol. Hematol.</i> 38:3-16, 2001.
	Kashmiri <i>et al.</i> , "Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49," <i>Hybridoma</i> 14:461-473, 1995.
	Padlan, "Anatomy of the antibody molecule," <i>Mol. Immunol.</i> 31:169-217, 1994.
	Reichman <i>et al.</i> , "Reshaping human antibodies for therapy," <i>Nature (London)</i> 332:323-327, 1988.

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT
BY APPLICANT**

Attorney Docket Number	4239-61725
Application Number	09/830,748
Filing Date	April 30, 2001
First Named Inventor	Kashmiri
Art Unit	1642
Examiner Name	Larry Ronald Helms

	Saldanha <i>et al.</i> , "A single backmutation in the human kIV framework of a previously unsuccessfully humanized antibody restores the binding activity and increases the secretion in cos cells," <i>Mol. Immunol.</i> 36:709-719, 1999.
	Schier <i>et al.</i> , "Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site," <i>J. Mol. Biol.</i> 263:551-567, 1996.
	Sha and Xiang, "A heavy-chain grafted antibody that recognizes the tumor-associated TAG72 antigen," <i>Cancer Biother.</i> 9:341-349, 1994.
	Sharkey <i>et al.</i> , "Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies," <i>Cancer Res.</i> 55:5935s-5945s.
	Slavin-Chiorini <i>et al.</i> , "Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins," <i>Cancer Res.</i> 55(23 Suppl.):5957s-5967s, 1995.
	Slavin-Chiorini <i>et al.</i> , "A CDR-grafted (humanized) domain-deleted antitumor antibody," <i>Cancer Biother. Radiopharm.</i> 12:305-316, 1997.
	Tamura <i>et al.</i> , "Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only," <i>J. Immunol.</i> 164:1432-1441, 2000.
	Wu <i>et al.</i> , "Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues," <i>J. Mol. Biol.</i> 294:151-162, 1999.
	Xiang <i>et al.</i> , "Complementarity determining region residues aspartic acid at H55, serine at H95 and tyrosines at H97 and L96 play important roles in the B72.3 antibody-TAG-72 antigen interaction," <i>Protein Eng.</i> 9:539-543, 1996.
	Xiang <i>et al.</i> , "Light-chain framework region residue Tyr71 of chimeric B72.3 antibody plays an important role in influencing the TAG72 antigen binding," <i>Protein Eng.</i> 12:417-421, 1999.
	Xiang <i>et al.</i> , "The tyrosine residue at position 97 in the VH CDR3 region of a mouse/human chimeric anti-colorectal carcinoma antibody contributes hydrogen bonding to the TAG72 antigen," <i>Cancer Biother.</i> 8:253-262, 1993.

EXAMINER SIGNATURE:	DATE CONSIDERED:
---------------------	---------------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.